Switzerland · Delayed Price · Currency is CHF Galderma Group AG Earnings Call Transcripts
Fiscal Year 2026
-
Record H1 2026 net sales of $3.1B, up 24.6% year-on-year, with strong double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year guidance was raised to 19%-21% net sales growth, with Nemluvio on track for $1B in sales.
-
Q1 2026 net sales rose 25.5% year-over-year to $1.473 billion, with double-digit growth across all segments and geographies. Full-year guidance for 17%-20% net sales growth and ~26% EBITDA margin is confirmed, supported by strong Dermatological Skincare and NEMLUVIO performance.
Fiscal Year 2025
-
Record net sales and profitability were achieved, driven by innovation and strong launches across all segments. Guidance for 2026 and the midterm was raised, with Nemluvio's peak sales expectations doubled and margin expansion anticipated.
-
Record net sales of $3.7B for the first nine months, up 15% year-on-year, with Q3 growth accelerating to 21%. Full-year guidance for net sales and EBITDA margin was raised, driven by strong performance in Nimluvio, neuromodulators, and skincare, with broad-based growth across geographies.
-
Record H1 2025 net sales of $2.45B (+12.2% y/y) driven by Nemluvio and Relfydess launches, with strong growth across all segments and geographies. Raised full-year sales guidance to 12%-14% and confirmed 23% EBITDA margin, while maintaining disciplined capital allocation and managing risks from tariffs and pricing pressures.
-
Record Q1 net sales of $1.129 billion, up 8.3% year-on-year, driven by strong launches and execution. Full-year guidance for 10%-12% net sales growth and 23% core EBITDA margin is confirmed, with tariff risks deemed manageable and international markets leading growth.
Fiscal Year 2024
-
Record 2024 results with $4.4B net sales (+9.3% YoY) and Core EBITDA over $1B, driven by strong international growth, innovation, and successful launches of Nemluvio and Relfydess. 2025 guidance targets 10–12% sales growth and 23% Core EBITDA margin, with continued investment in launches.
-
Record net sales of $3.3B and 9.2% year-on-year growth were driven by strong international and product category performance, with injectable aesthetics and dermatological skincare leading. Guidance for full-year net sales growth was narrowed to 8.8%-9.5%, and Core EBITDA margin is expected to match 2023.
-
A new scientific partnership and minority shareholding by L'Oréal aims to accelerate innovation in dermatology, leveraging both companies' complementary strengths while maintaining strategic independence and competitive positioning. The R&D collaboration is in early stages, with project details yet to be finalized.
-
Record H1 2024 net sales of $2.2B (+10.8% y/y) driven by strong growth in injectable aesthetics, skincare, and international markets. Core EBITDA margin expanded to 23.4%, with leverage reduced to 2.6 turns. Full-year net sales guidance raised to the upper end of the 7%-10% range.